- Blonanserin
-
- $2.00 / 1kg
-
2019-07-06
- CAS:236395-14-5
- Min. Order: 1kg
- Purity: 9%
- Supply Ability: 100kg
|
| | BIA 2-093 Basic information |
| Product Name: | BIA 2-093 | | Synonyms: | Sep 0002093;(S)-5-CarbaMoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate;5H-Dibenz[b,f]azepine-5-carboxaMide, 10-(acetyloxy)-10,11-dihydro-, (10S)-;Acetic acid 5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10(S)-yl ester;Eslicarbazepine acetate Impurity;S-Licarbazepine Acetate;(10S)-10-(Acetyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxaMide;(S)-(-)-10-ACETOXY-10,11-DIHYDRO-5H-DIBENZO/B,F/AZEPINE-5-CARBOXAMIDE- | | CAS: | 236395-14-5 | | MF: | C17H16N2O3 | | MW: | 296.32 | | EINECS: | 636-617-2 | | Product Categories: | Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;APIs | | Mol File: | 236395-14-5.mol |  |
| | BIA 2-093 Chemical Properties |
| Melting point | 183-185°C | | Boiling point | 427.4±55.0 °C(Predicted) | | density | 1.32 | | storage temp. | Sealed in dry,2-8°C | | solubility | H2O: insoluble | | form | solid | | pka | 13.97±0.40(Predicted) | | color | white | | InChIKey | QIALRBLEEWJACW-INIZCTEOSA-N |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | HS Code | 2934.99.3000 |
| | BIA 2-093 Usage And Synthesis |
| Description | Although epilepsy is a neurological disorder with varying etiology
and severity, the common feature is unprovoked, recurring seizures.
Even when traditional AEDs, such as phenobarbital,
phenytoin, carbamazepine, and valproate, control seizure activity, their
effectiveness is hampered by considerable side effects and the tendency
for drug-drug interactions. Designed for improved efficacy and safety,
eslicarbazepine acetate is a third-generation AED that has been approved
as adjunctive therapy for partial-onset seizures with or without secondary generalization. As a member of the carbamazepine family (first generation), it is the prodrug of eslicarbazepine and the active metabolite of
oxcarbazepine (second generation).
. | | Description | Eslicarbazepine acetate is a sodium channel blocker (IC50 = 138 nM in a radioligand binding assay). It inhibits sodium uptake in a dose-dependent manner in rat cortical synaptosomes at concentrations ranging from 30-300 μM. In vivo, oral and i.p. administration of eslicarbazepine acetate is protective against seizures induced by maximal electroshock (MES) in mice with ED50 values of 4.7 and 6.3 mg/kg, respectively, which are well below the median toxic dose (TD50) values of 358.7 and 78.6 mg/kg for oral and i.p. administration respectively. High-dose administration (30 mg/kg) of eslicarbazepine acetate prevents picrotoxin-induced seizures in rats. Low-dose administration (10 mg/kg) does not suppress picrotoxin-induced seizures, however, it reduces seizure number and duration. Formulations containing eslicarbazepine acetate have been used for the treatment of partial-onset seizures. | | Chemical Properties | White to Off-White Solid | | Originator | BIAL Group (Spain) | | Uses | Eslicarbazepine acetate, (BIA 2-093), is a promising antiepileptic drug structurally related to Carbamazepine and Oxcarbazepine. Neuroprotective & Neuroresearch product. | | Definition | ChEBI: The acetate ester, with S configuration, of licarbazepine. An anticonvulsant, it is approved for use in Europe and the United States as an adjunctive therapy for epilepsy. | | Brand name | Zebinix; Exalief, Stedesa | | Side effects | The most
common adverse events occurring with an incidence of >2% were dizziness, somnolence, nausea, diplopia, headache, vomiting, abnormal coordination, blurred vision, vertigo, and fatigue. While most of these side effects appeared to be mild to moderate, they did display a dose dependency. Although eslicarbazepine acetate is only contraindicated in patients with a known hypersensitivity to the carbamazepine family of AEDs, caution should be exercised in patients with cardiac conduction abnormalities (potential for prolongations in PR intervals), renal impairment, and in patients of Han Chinese and Thai origin since the presence of HLA-B*1502 allele in these individuals has been shown to be strongly associated with the risk of developing Stevens-Johnson syndrome. Regarding drug interactions, eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives, so alternative or additional methods of contraception should be considered. |
| | BIA 2-093 Preparation Products And Raw materials |
|